Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Inclusion Criteria: * Male or female subjects must be greater than or equal to 18 years of age * Subjects must have a diagnosis of Systemic Sclerosis * Subjects must have a diagnosis or history of Raynaud's Phenomenon * Subjects must have a minimum of 10 symptomatic Raynaud's Phenomenon attacks * Female subjects of childbearing potential and male subjects must agree to use contraception for the duration of the study * Subjects must be willing and able to comply with the study requirements and give informed consent for participation in the study Exclusion Criteria: * Female subjects who are pregnant or breastfeeding * Subjects with systolic blood pressure \<85 mmHg * Subjects with an estimated glomerular filtration rate \<30 mL/min/1.73 m2 * Subjects with Child-Pugh Class B or Class C liver disease or an alanine aminotransferase and/or aspartate aminotransferase value \>3 × the upper limit of normal at screening. * Subjects with gangrene, digital ulcer infection, or requirement of cervical or digital sympathectomy * Subjects with intractable diarrhea or vomiting * Subjects with a risk of clinically significant bleeding events including those with coagulation or platelet disorders * Subjects with a history of major trauma or hemorrhage * Subjects with clinically significant chronic intermittent bleeding such as active gastric antral vascular ectasia or active peptic ulcer disease * Subjects who have had any cerebrovascular events * Subjects with a history of myocardial infar…